New study to see if emicizumab protects Kids' joints from hemophilia damage
NCT ID NCT07190118
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 20 children with hemophilia A who are starting emicizumab treatment. Researchers will measure pain, joint health, balance, and mobility over time to see if the drug helps protect the musculoskeletal system. The goal is to understand whether emicizumab can reduce long-term joint problems in these children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emicizumab
What this could lead to
If successful, this could show that emicizumab helps protect joints and muscles in children with hemophilia A, potentially improving their long-term physical health.
What could go wrong
This is a small, early-stage study with only 20 participants and no control group. Results may not apply to all children with hemophilia A, and the treatment's long-term effects on joints are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hasan Kalyoncu University
Gaziantep, Gaziantep, (505) 090-5846, Turkey (Türkiye)